Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

203 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
How to develop a successful cancer drug--molecules to medicines or targets to treatments?
Newell DR. Newell DR. Eur J Cancer. 2005 Mar;41(5):676-82. doi: 10.1016/j.ejca.2004.12.024. Eur J Cancer. 2005. PMID: 15763642 Review.
The EORTC Laboratory Research Division. European Organisation for Research and Treatment of Cancer.
BrĂ¼nner N, Double J, Fichtner I, Gescher A, Newell D, Oosterhuis W, Price P. BrĂ¼nner N, et al. Among authors: newell d. Eur J Cancer. 2002 Mar;38 Suppl 4:S14-8. doi: 10.1016/s0959-8049(01)00455-5. Eur J Cancer. 2002. PMID: 11858958
The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition.
Haagensen EJ, Kyle S, Beale GS, Maxwell RJ, Newell DR. Haagensen EJ, et al. Among authors: newell dr. Br J Cancer. 2012 Apr 10;106(8):1386-94. doi: 10.1038/bjc.2012.70. Epub 2012 Mar 13. Br J Cancer. 2012. PMID: 22415236 Free PMC article.
Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells.
Johnson N, Bentley J, Wang LZ, Newell DR, Robson CN, Shapiro GI, Curtin NJ. Johnson N, et al. Among authors: newell dr. Br J Cancer. 2010 Jan 19;102(2):342-50. doi: 10.1038/sj.bjc.6605479. Epub 2009 Dec 15. Br J Cancer. 2010. PMID: 20010939 Free PMC article.
Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK.
Newell DR, Searle KM, Westwood NB, Burtles SS; Cancer Research UK Phase I/II Clinical Trials Committee. Newell DR, et al. Br J Cancer. 2003 Aug 4;89(3):437-54. doi: 10.1038/sj.bjc.6601106. Br J Cancer. 2003. PMID: 12888809 Free PMC article. No abstract available.
Decreased telomerase activity is not a reliable indicator of chemosensitivity in testicular cancer cell lines.
Cressey TR, Tilby MJ, Newell DR. Cressey TR, et al. Among authors: newell dr. Eur J Cancer. 2002 Mar;38(4):586-93. doi: 10.1016/s0959-8049(01)00406-3. Eur J Cancer. 2002. PMID: 11872354
The impact of p53 status on cellular sensitivity to antifolate drugs.
Lu X, Errington J, Curtin NJ, Lunec J, Newell DR. Lu X, et al. Among authors: newell dr. Clin Cancer Res. 2001 Jul;7(7):2114-23. Clin Cancer Res. 2001. PMID: 11448931
Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro.
Bowman KJ, Newell DR, Calvert AH, Curtin NJ. Bowman KJ, et al. Among authors: newell dr. Br J Cancer. 2001 Jan 5;84(1):106-12. doi: 10.1054/bjoc.2000.1555. Br J Cancer. 2001. PMID: 11139322 Free PMC article.
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.
Delaney CA, Wang LZ, Kyle S, White AW, Calvert AH, Curtin NJ, Durkacz BW, Hostomsky Z, Newell DR. Delaney CA, et al. Among authors: newell dr. Clin Cancer Res. 2000 Jul;6(7):2860-7. Clin Cancer Res. 2000. PMID: 10914735
Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT).
Monks NR, Calvete JA, Curtin NJ, Blakey DC, East SJ, Newell DR. Monks NR, et al. Among authors: newell dr. Br J Cancer. 2000 Jul;83(2):267-9. doi: 10.1054/bjoc.2000.1240. Br J Cancer. 2000. PMID: 10901381 Free PMC article.
203 results
Jump to page